Cardiomyopathy Clinical Trials

The cardiomyopathy clinical trials team is interested in seeing how exciting new cardiomyopathy drugs and devices can help to improve the outcomes and quality of life for those living with the cardiomyopathy disease.

Feel free to call or e-mail the Knight Cardiovascular Institute research team at 503-418-1964 or by emailing heartresearch@ohsu.edu. You will then be forwarded to the appropriate research team member who will be able to see if you qualify for any of the clinical trials being offered at OHSU.

You can also find all the of heart failure clinical trials, that are currently enrolling patients, below.

BeAT-HF

Barostim Neo® - BarofleActivation Therapy for Heart Failure

Primary investigator:

Albert Camacho, M.D.

Protocol number:

IRB00015725

Study purpose:

The purpose of this study is to learn if the study device is safe and works in improving heart failure symptoms as well as the quality of life for those living with heart failure. The study device is meant to stimulate an artery in the neck that will send signals to the brain telling blood vessels to relax, the heart to slow down and stop sending stress hormones, and the kidneys to reduce the amount of fluid in the body.

Contact:

John Halvorson (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

CAPACITY-HF

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction (CAPACITY HFpEF)

Primary investigator:

Albert Camacho, M.D.

Sub investigators:

Protocol number:

IRB00017719

Study purpose:

The purpose of this study is to learn more about a study drug called IW1973-204 and how it can help to improve exercise capacity in those with heart failure with preserved ejection fraction. 

Contact:

John Halvorson (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

HCM Pilot Study

Hypertrophic Cardiomyopathy Pilot Study

Primary investigator:

Larisa Tereshchenko, M.D., Ph.D.

Sub investigators:

Protocol number:

IRB00015049

Study purpose:

This study evaluates mechanisms of arrythmogenicity in hypertrophic cardiomyopathy, in comparison to patients with well-understood arrhythmogenic substrate (ischemic cardiomyopathy), as well as to individuals free from arrhythmogenic substrate.

Contact:

Nichole Rogovoy (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

LIFE STUDY

Entresto™(LCZ696) in Advance Heart Failure

Primary investigator:

Albert Camacho, M.D.

Protocol number:

IRB00016277

Study purpose:

The purpose of this study is to test whether the study drug (Entresto®) improves heart failure symptoms and outcomes in persons with advanced heart failure in comparison to treatment with valsartan alone over 24 weeks. 

Contact:

John Halvorson (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

MAVERICK-HCM

A Randomized, Double-blind, Pacebo-controlled, Concentration-guided, Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

Primary investigator:

Stephen Heitner, M.D.

Sub investigators:

Protocol number:

IRB00018173

Study purpose:

The purpose of this study is to evaluate the effect of the investigational drug, mavacamten, compared to a placebo (an inactive drug) in patients with non-obstructive HCM. This is being done to confirm that mavacamten is safe, and can be tolerated and to study whether it helps to improve symptoms or ability to exercise.

Contact:

Katie McCullough (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

MOMENTUM 3

Multi-Center Study oMaglev Technology in Patients Undergoing MCS Therapy in HeartMate 3

Primary investigator:

Frederick Tibayan, M.D.

Protocol number:

IRB00016427

Study purpose:

The purpose of this study is to evaluate the effect of the investigational drug, mavacamten, compared to a placebo (an inactive drug) in patients with non-obstructive HCM. This is being done to confirm that mavacamten is safe, and can be tolerated and to study whether it helps to improve symptoms or ability to exercise.

Contact:

John Halvorson (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

MYK-491-003 HF-SAD

Randomized, Double-blind, Crossover, Placebo-controlled, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Patients with Stable Heart Failure.

Primary investigator:

Albert Camacho, M.D.

Sub investigators:

Protocol number:

IRB00017910

Study purpose:

The purpose of this study is to learn more about a study drug called MYK-491. This will be an inpatient study to determine if the study drug will help the heart pump more efficiently with each beat, if the study drug is safe in those with heart failure, what the side effects of the drug is, and how much of the drug is in the blood.

Contact:

John Halvorson (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu